10-K: Aflac Reports 2023 Financial Results, Cites Strong Capital Position and Strategic Growth

Aflac Incorporated's 2023 annual report reveals a complex financial landscape with revenue declines offset by earnings growth and strategic capital management.

Summary

• Aflac Incorporated's total revenues decreased by 2.3% to $18.7 billion in 2023.
• Net earnings for the year were $4.7 billion, or $7.78 per diluted share, an increase from $4.4 billion, or $6.93 per diluted share, in 2022.
• Adjusted earnings for 2023 were $3.7 billion, or $6.23 per diluted share, compared to $3.6 billion, or $5.67 per diluted share, in 2022.
• The average yen/dollar exchange rate weakened by 7.4% in 2023, negatively impacting adjusted earnings per diluted share by $0.19.
• The company repurchased 38.9 million shares for $2.8 billion in 2023 and has 77.7 million shares remaining authorized for repurchase.
• Shareholders equity was $22.0 billion, or $38.00 per share, at December 31, 2023, compared with $20.1 billion, or $32.73 per share, at December 31, 2022.
• The annualized return on average shareholders equity in 2023 was 22.1%.
• Adjusted book value was $27.5 billion, or $47.55 per share at December 31, 2023, compared with $26.6 billion, or $43.18 per share, at December 31, 2022.
• The annualized adjusted return on equity excluding foreign currency impact in 2023 was 14.2%.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with both positive and negative aspects. While earnings and capital management are strong, revenue declines and external economic risks temper the overall outlook. The sentiment is cautiously optimistic.

Positives

• Net earnings and adjusted earnings per share increased year-over-year.
• The company demonstrated a commitment to returning capital to shareholders through share repurchases and increased dividends.
• Aflac Japan's new annualized premium sales increased, driven by new product launches.
• Aflac U.S. saw growth in life, disability, dental, and vision products.
• The company maintains strong capital ratios in both Aflac Japan and Aflac U.S.

Negatives

• Total revenues decreased by 2.3% in 2023.
• The yen/dollar exchange rate weakened, negatively impacting adjusted earnings.
• Aflac Japan's net earned premiums decreased due to internal reinsurance transactions and limited-pay products reaching paid-up status.
• Aflac U.S. experienced higher operating expenses due to investments in the U.S. platform and employee-related costs.

Risks

• The company is exposed to difficult conditions in global capital markets and the economy, including inflation.
• Defaults and credit downgrades of investments could negatively impact the company's financial results.
• The company is exposed to significant interest rate risk, which may adversely affect its results of operations.
• The company's concentration of business in Japan poses risks to its operations and financial condition.
• The company is exposed to foreign currency fluctuations in the yen/dollar exchange rate.
• The company's sales are dependent on its ability to attract and retain qualified sales associates, brokers and employees.
• Extensive regulation and changes in legislation can impact profitability and growth.
• Catastrophic events, including those as a result of climate change or major public health issues, could adversely affect the company's financial condition and results of operations.

Future Outlook

The company's objectives in 2024 are to maintain strong pretax margins with increased sales production through product refreshment in its Aflac Japan segment and to begin realizing benefits from its buy to build initiatives and other platform investments, manage expenses and strengthen the number of career agents for Aflac U.S.

Management Comments

• The Company believes that its strategy of positioning itself for future growth and efficiency while defending and leveraging its market-leading position, powerful brand recognition and diverse distribution in Japan and the U.S. will provide support toward these objectives.
• The Company intends to maintain strong capital ratios in Aflac Japan and Aflac U.S. in support of its commitment to shareholder dividends while remaining tactical in its deployment of capital in the form of share repurchases and opportunistic investments.

Industry Context

The report highlights the impact of global economic conditions, regulatory changes, and competitive pressures on the insurance industry, particularly in the supplemental health insurance market. The company is adapting to changing customer demographics and preferences, as well as the increasing importance of digital sales methods.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards, but it does mention that Aflac Japan is the largest insurer in Japan in terms of cancer and medical policies in force.
• The report also notes that Aflac U.S. competes against several supplemental insurance carriers on a national and regional basis.
• The company believes its policies, premium rates, platforms, value-added services and sales commissions are competitive by product type.
• The company believes that its products are distinct from competitive offerings given its product focus, distribution capabilities and brand awareness.

Management Changes

Legal Proceedings

• The Company is a defendant in various lawsuits and receives various regulatory inquiries considered to be in the normal course of business.
• The Company believes the outcome of pending litigation will not have a material adverse effect on its financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders will benefit from increased dividends and share repurchases.
• Employees may experience changes in compensation and benefits due to the company's strategic initiatives.
• Customers may see new and enhanced products and services.
• Suppliers and creditors may be affected by the company's financial performance and strategic decisions.

Next Steps

• The company will pursue growth through product development and distribution expansion.
• The company will achieve efficiencies by modernizing its technology and streamlining its operations.
• The company will maintain strong capital ratios in Aflac Japan and Aflac U.S.
• The company will remain tactical in its deployment of capital in the form of share repurchases and opportunistic investments.

Key Dates

Keywords

Aflac, insurance, financial results, earnings, revenue, Japan, United States, capital, share repurchase, dividends, investment, risk, exchange rate, supplemental health, policyholders